Market closed

SCYNEXIS/$SCYX

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About SCYNEXIS

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Ticker

$SCYX

Sector

Health Care

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Jersey City, United States

Employees

Website

www.scynexis.com

SCYNEXIS Metrics

BasicAdvanced

$44M

-

-$0.78

1.50 -

Price and volume

Market cap

$44M

Beta

1.5

52-week high

$3.07

52-week low

$0.90

Average daily volume

280K

Financial strength

Current ratio

3.129

Quick ratio

3.052

Long term debt to equity

3.902

Total debt to equity

27.163

Interest coverage (TTM)

-21.35%

Management effectiveness

Return on assets (TTM)

-26.72%

Return on equity (TTM)

-48.42%

Valuation

Price to revenue (TTM)

6.544

Price to book

0.75

Price to tangible book (TTM)

0.75

Price to free cash flow (TTM)

-2.567

Growth

Revenue change (TTM)

-93.70%

Earnings per share change (TTM)

-151.84%

3-year revenue growth (CAGR)

-11.99%

3-year earnings per share growth (CAGR)

-33.03%

What the Analysts think about SCYNEXIS

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for SCYNEXIS stock.

SCYNEXIS Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

SCYNEXIS Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

SCYNEXIS News

AllArticlesVideos

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewsWire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SCYX

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for SCYNEXIS stock?

SCYNEXIS (SCYX) has a market cap of $44M as of January 15, 2025.

What is the P/E ratio for SCYNEXIS stock?

The price to earnings (P/E) ratio for SCYNEXIS (SCYX) stock is 0 as of January 15, 2025.

Does SCYNEXIS stock pay dividends?

No, SCYNEXIS (SCYX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next SCYNEXIS dividend payment date?

SCYNEXIS (SCYX) stock does not pay dividends to its shareholders.

What is the beta indicator for SCYNEXIS?

SCYNEXIS (SCYX) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.